Bio-Techne Corporation (TECH) has recently been included and altered in the portfolios of Weitz Partners III Opportunity Fund and Ieq Capital LLC. Providers like Private Advisor Group LLC, Handelsbanken Fonder AB, and New York State Common Retirement Fund remain invested in TECH. However, Principal Financial Group Inc. and Pembroke Management LTD lowered their positions. Bio-Techne is persistently proactive in investor conferences highlighting their progress. The corporation showcased strong revenue growth in their Q2 2025 earnings call and declared dividends. The latest stock adjustments show interesting movements with stocks hitting a new 12-month low followed by a price target adjustment by Argus. There was a positive hike in stock as Bio-Techne outperformed Q2 FY25 expectations. With noteworthy advancements such as their strategic co-marketing agreement, release of GMP TcBuster Non-Viral Genome Engineering System, distribution contracts, and a significant investment in Spear Bio; Bio-Techne showcases their commitment to constant innovation. Their latest product launches comprise an expanded RNAscope menu, ESR1 Mutation Monitoring Assay, and the AI-Engineered Designer Protein Portfolio. Also, they've been efficacious in legal battles on antibody patent and reverse engineering against Miltenyi Biotec.
Bio-Techne Corp TECH News Analytics from Mon, 08 Apr 2024 07:00:00 GMT to Sat, 01 Mar 2025 09:05:26 GMT -
Rating 2
- Innovation 8
- Information 7
- Rumor 5
